Daphne Karydas sold $86k of MLYS
director at Mineralys Therapeutics, Inc.. 3,000 shares at an average of $28.58, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +15RoleDirector
- +9Trade size$86k at market
- +10Share of holdings soldSold 33% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001816952-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +3,000 | $12.02 | $36k | 9,200 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -3,000 | $28.58 | $86k | 6,200 | 25 d ago |
| Sep 15, 2026 | MOption exercise Stock Optionderivative10b5-1 | -3,000 | $0.00 | $0 | 35,000 | 25 d ago |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 16Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $409k 11,367 shares | -12% | |
| 56Moderate | Mineralys Therapeutics, Inc. | Srinivas Akkaraju director | $15M 588,235 shares | - | |
| 49Moderate | Mineralys Therapeutics, Inc. | Ra Capital Management, L.p. director | $30M 1,176,470 shares | +27% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $147k 11,365 shares | -11% | |
| 65Notable | Mineralys Therapeutics, Inc. | Adam Scott Levy CFO and Secretary | $1.1M 73,678 shares | -36% | |
| 33Weak | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $230k 15,884 shares | -2% | |
| 28Weak | Mineralys Therapeutics, Inc. | Adam Scott Levy CFO and Secretary | $155k 10,758 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.